KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Junlong Wu, Xinghai Li, Chengyuan Gu, Lixin Hua, Ranlu Liu, Jun Li, Mingxing Qiu, Jianming Guo, Haiying Dong, Zhigang Ji, Liping Xie, Shaoxing Zhu, Xuhui Zhang, Peng Chen, Shusuan Jiang, Zhongquan Sun, Danfeng Xu, Hui Chen, Benkang Shi, Yujie Wang, Jinxian Pu, Frank Perabo, Yuanwei Chen, Dingwei Ye

Signal Transduct Target Ther 11(1) 131

PMID41968137
PMCIDPMC13071078
DOI10.1038/s41392-026-02618-3
发表日期2026-04-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Metastatic castration-resistant prostate cancer (mCRPC) after treatment with docetaxel and androgen receptor signaling inhibitors (ARSIs) has limited treatment options. Although enzalutamide has shown activity after abiraterone and docetaxel, robust evidence from randomized phase III trials is lacking. Deutenzalutamide, a novel derivative with slower metabolism and improved pharmacokinetics, may offer enhanced safety and efficacy. This phase III, double-blind trial conducted at 36 centers in China enrolled patients whose disease progressed on or who were intolerant to abiraterone and docetaxel, or who were ineligible for docetaxel. Patients were randomized (2:1) to receive deutenzalutamide 80 mg once daily or placebo until progression or unacceptable toxicity; the primary endpoint was radiographic progression-free survival (rPFS). Of 417 patients (276 deutenzalutamide; 141 placebo), all had previously received abiraterone, and 68% had also received docetaxel. Deutenzalutamide significantly improved rPFS (HR, 0.58; P = 0.0001), reducing the risk of progression by 42%. Although the initial OS analysis was not significant (HR, 0.95), sensitivity analyses adjusting for subsequent therapies showed significant OS benefits (HR, 0.65-0.73). Treatment-related grade 3 or higher adverse events occurred in 22.3% of patients treated with deutenzalutamide, compared with 15.0% with placebo. The most common treatment-related adverse event was anemia, reported at any grade in 21.2% versus 17.9%, with grade 3/4 anemia in 6.6% versus 2.9%, respectively. Notably, no seizures or falls were reported. In summary, deutenzalutamide significantly prolonged rPFS and, after adjustment, showed a potential OS benefit with a favorable safety profile, supporting its promise as a new treatment option for mCRPC. Clinical trial registration: NCT03851640.

KM 提取结果

2 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2 Kaplan‒Meier estimates of rPFS assessed by ( a ) investigators and ( b ) blinded independent central review. The HR and 95% CI for the difference between treatment groups in rPFS were estimated using the stratified Cox regression model, including treatment as the explanatory variable. Analyses were performed on the intention-to-treat population. HR hazard ratio, rPFS radiographic progression-free survival, CI confidence interval

A

radiographic progression-free survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

radiographic progression-free survival

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure3 个面板

Fig. 4

Fig. 4 Final analyses of OS. The HR and 95% CI for the difference between treatment groups in OS were estimated using the stratified Cox regression model, including treatment as the explanatory variable. a Kaplan‒Meier estimates of OS unadjusted for patients who received subsequent antitumor therapy. The differences in OS in this final analysis were not statistically significant on the basis of the allocated two-sided alpha level of 0.05. b , c Kaplan‒Meier estimates of OS adjusted for patients who received subsequent antitumor therapy, applying the naïve censoring method and the IPCW method ( b ) and the RPSFTM method ( c ). Patients at risk are not included in the IPCW model due to the lack of a clear clinical interpretation of the number of patients at risk associated with the weighted methodology. Analysis was performed on the intention-to-treat population. OS overall survival, IPCW inverse probability of censoring weighting, RPSFTM rank preserving structural failure time models

A

Overall survival

Fig. 4 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:extreme upward reversal
查看结果
B

Overall survival

Fig. 4 · Panel B

failed 待 EXE 对齐 预期 2 条 已提取 0 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 0 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
No curves extracted
查看结果
C

Overall survival

Fig. 4 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial profile. ADT androgen deprivation therapy
非 KM Figure
Fig. 3Fig. 3 Prespecified subgroup analyses of rPFS assessed by investigators in all patients. Analysis of selected subgroups of interest within the overall population was performed at each subgroup level with the use of a Cox proportional-hazards model. a Nonstratified analysis
非 KM Figure